Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.

Lignende værker

• Efficacy of LY333328 against Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis
  af: Kaatz, Glenn W., et al.
  Udgivet: (1998)
• Influence of Human Serum on Pharmacodynamic Properties of an Investigational Glycopeptide, LY333328, and Comparator Agents against Staphylococcus aureus
  af: Zhanel, George G., et al.
  Udgivet: (1998)
• Synergy of an Investigational Glycopeptide, LY333328, with Once-Daily Gentamicin against Vancomycin-Resistant Enterococcus faecium in a Multiple-Dose, In Vitro Pharmacodynamic Model
  af: Zelenitsky, S. A., et al.
  Udgivet: (1999)
• Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
  af: Zelenitsky, S A, et al.
  Udgivet: (1997)
• Activity of Oritavancin (LY333328), an Investigational Glycopeptide, Compared to That of Vancomycin against Multidrug-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model
  af: Coyle, Elizabeth A., et al.
  Udgivet: (2001)